Moderna and Merck's melanoma vaccine trial data sparks stock sell-off

Merck: Merck is a global pharmaceutical company with a strong portfolio in oncology, including its established immunotherapy Keytruda. It is collaborating with Moderna on a personalized mRNA vaccine targeting melanoma recurrence, with the latest trial findings generating enthusiasm among doctors for their clinical implications. The data release highlighted the combination therapy's role in improving outcomes beyond standard care. Moderna: Moderna is a biotechnology company focused on developing mRNA-based vaccines and therapeutics for infectious diseases, cancer, and other conditions. It is partnering with Merck on a personalized mRNA cancer vaccine for melanoma, where recent Phase 3 trial data drew positive reactions from oncologists for advancing treatment options. The results followed earlier trial success announcements and were released early due to a leak ahead of a major medical conference. Investor Reaction: Wall Street responded with a sell-off in the companies' shares, reflecting a disconnect from the medical community's positive view of the data. Oncology Response: Oncologists and trial investigators have praised the findings as a clinically meaningful advance and potential new benchmark in adjuvant melanoma treatment. Trial Data Release: The companies released full Phase 3 results early after details leaked online, confirming the vaccine's benefit when added to existing immunotherapy.